AlveoliX AG

Switzerland
Bulle, Fribourg, Switzerland, 3010

Company profile

AlveoliX AG company profile

AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at improving preclinical decision-making and thus reducing drug development costs. AlveoliX aims at changing the way drug development research is done today by providing in-vitro models that reproduce the in-vivo environment in an unprecedented way. These in-vitro models, called organ-on-chips, will make it possible to better predict drugs’ responses in humans than standard in-vitro and in-vivo models and as a consequence to importantly reduce animal testing.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$50,000+
Founded
2019-01-01, Year

Headquarters

Postal code
3010
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
3
Last funding
Grant / 2019-03-19
Investors
1
Lead investors
1
Founders
1
Articles
2

Founders and investors

Founders

Janick Stucki

Lead investors

Eurostars

Investors

Eurostars